1. Home
  2. IPSC vs ZYXI Comparison

IPSC vs ZYXI Comparison

Compare IPSC & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPSC
  • ZYXI
  • Stock Information
  • Founded
  • IPSC 2019
  • ZYXI 1996
  • Country
  • IPSC United States
  • ZYXI United States
  • Employees
  • IPSC N/A
  • ZYXI N/A
  • Industry
  • IPSC Medicinal Chemicals and Botanical Products
  • ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • IPSC Health Care
  • ZYXI Health Care
  • Exchange
  • IPSC Nasdaq
  • ZYXI Nasdaq
  • Market Cap
  • IPSC 49.1M
  • ZYXI 44.8M
  • IPO Year
  • IPSC 2021
  • ZYXI N/A
  • Fundamental
  • Price
  • IPSC $0.57
  • ZYXI $1.39
  • Analyst Decision
  • IPSC Strong Buy
  • ZYXI Hold
  • Analyst Count
  • IPSC 5
  • ZYXI 3
  • Target Price
  • IPSC $3.33
  • ZYXI $3.00
  • AVG Volume (30 Days)
  • IPSC 730.7K
  • ZYXI 74.4K
  • Earning Date
  • IPSC 11-04-2025
  • ZYXI 10-30-2025
  • Dividend Yield
  • IPSC N/A
  • ZYXI N/A
  • EPS Growth
  • IPSC N/A
  • ZYXI N/A
  • EPS
  • IPSC N/A
  • ZYXI N/A
  • Revenue
  • IPSC $114,128,000.00
  • ZYXI $144,808,000.00
  • Revenue This Year
  • IPSC $1,589.94
  • ZYXI N/A
  • Revenue Next Year
  • IPSC N/A
  • ZYXI $7.07
  • P/E Ratio
  • IPSC N/A
  • ZYXI N/A
  • Revenue Growth
  • IPSC 5491.77
  • ZYXI N/A
  • 52 Week Low
  • IPSC $0.34
  • ZYXI $1.23
  • 52 Week High
  • IPSC $1.83
  • ZYXI $9.42
  • Technical
  • Relative Strength Index (RSI)
  • IPSC 60.85
  • ZYXI 39.33
  • Support Level
  • IPSC $0.52
  • ZYXI $1.42
  • Resistance Level
  • IPSC $0.62
  • ZYXI $1.51
  • Average True Range (ATR)
  • IPSC 0.03
  • ZYXI 0.06
  • MACD
  • IPSC 0.01
  • ZYXI 0.00
  • Stochastic Oscillator
  • IPSC 64.94
  • ZYXI 27.44

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

About ZYXI Zynex Inc.

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

Share on Social Networks: